Contineum Therapeutics, Inc. (CTNM) vs TRex Bio Inc. (TRXB)

Contineum Therapeutics, Inc. CTNM 9.42 +6.92%
TRex Bio Inc. TRXB 13.26 +2.08%

Contineum Therapeutics, Inc. and TRex Bio Inc. are both Biotechnology companies. Contineum Therapeutics, Inc. and TRex Bio Inc. are of similar size ($356.5M and $345.9M).

Metric	CTNM	TRXB	Biotechnology median
P/E	n/m	—	10.60
P/S	n/m	—	9.40
P/B	1.47	—	2.13
Price to free cash flow	n/m	—	25.18
EV/EBITDA	n/m	—	0.66
EV/Sales	n/m	—	9.02
Earnings yield	(18.76%)	—	(32.88%)
Free cash flow yield	(14.44%)	—	(23.13%)

Metric	CTNM	TRXB	Biotechnology median
Gross margin	—	—	68.51%
Operating margin	0.00%	—	0.00%
Net margin	0.00%	—	0.00%
Free cash flow margin	0.00%	—	0.00%
Return on equity	(29.80%)	—	(51.96%)
Return on assets	(28.34%)	—	(46.06%)
Return on invested capital	(4,845.62%)	—	0.00%

Metric	CTNM	TRXB	Biotechnology median
Revenue growth (TTM)	—	—	6.76%
EPS growth (last fiscal year)	0.46%	—	29.88%
Revenue growth, 5-year CAGR	—	—	9.75%
Net income growth, 5-year CAGR	—	—	0.00%

Metric	CTNM	TRXB	Biotechnology median
Debt to equity	0.00	—	0.00
Current ratio	31.11	—	4.97
Net debt to EBITDA	3.88	—	1.01

Metric	CTNM	TRXB	Biotechnology median
Dividend yield	—	—	0.41%
Payout ratio	—	—	—

Metric	CTNM	TRXB	Biotechnology median
Market cap	345.93m	356.52m	161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack